MedPath
FDA Approval

Ondansetron

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 1, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ondansetron(2 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Hikma Pharmaceuticals USA Inc.

001230762

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ondansetron

Product Details

NDC Product Code
0641-6080
Application Number
ANDA077541
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
April 1, 2022
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 0.5 mg in 1 mL
Code: NMH84OZK2BClass: ACTIMQuantity: 2 mg in 1 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 9 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
TRISODIUM CITRATE DIHYDRATEInactive
Code: B22547B95KClass: IACTQuantity: 0.25 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath
Ondansetron - FDA Approval | MedPath